Rogo, Aidoc, Hightouch raise $460M

Applied AI just had a very loud funding day. On April 29, Rogo, Aidoc, and Hightouch announced big rounds that add up to $460 million — $160 million for finance, $150 million for healthcare, and $150 million for marketing. That matters because these are not vague “AI for everything” stories. They are workflow companies. They plug into places where enterprises already spend money and can measure results fast. (rogo.ai) ### Who raised what? Rogo said it raised a $160 million Series D led by Kleiner Perkins, with Sequoia, Thrive Capital, Khosla Ventures, J.P. Morgan Growth Equity Partners, BoxGroup, Mantis VC, Jack Altman, Evantic, and Positive Sum also in the round. Aidoc announced a $150 million Series E led by Growth Equity at Goldman Sachs Alternatives, with General Catalyst, SoftBank Vision Fun(rogo.ai)h said it raised a $150 million Series D at a $2.75 billion valuation, led by Goldman Sachs and Bain Capital Ventures. (rogo.ai) ### Why do these three fit together? Because each one sells AI into a department with a clear owner and a clear budget. Rogo targets investment banks, asset managers, and private equity firms. Aidoc sells clinical AI into health systems. Hightouch sells an “agentic marketing platform” and customer data tooling to enterprise marketing teams. Different buyers, same pattern — AI attach(rogo.ai)cience project. (rogo.ai) ### What does Rogo actually do? Rogo is basically building AI coworkers for finance teams. The company says it is already deployed across many top investment banks, asset managers, and private equity firms. That is important because finance buyers are picky, security-heavy, and deeply workflow-driven. If a product lands there, it usually means it is solving a narrow but painful prob(rogo.ai)screening, or internal knowledge retrieval — well enough to survive real deal work. (rogo.ai) ### Why is Aidoc a different kind of bet? Healthcare AI has a harder bar. The product cannot just save time — it has to fit into clinical workflows and, in many cases, deal with regulation and validation. Aidoc says the new money will expand its clinical foundation model and enterprise platform, and it now has over $500 million in total funding. The company also says it has deployme(rogo.ai)ms and more than 1,600 hospitals worldwide, which makes this look less like early experimentation and more like scale-up capital. (aidoc.com) ### And Hightouch? Hightouch sits in another very budgeted part of the enterprise — marketing. Its pitch is that AI should not just generate copy but actually use customer data, brand context, and activation channels to run better campaigns. The company says it has 803 payin(aidoc.com)are layer that turns enterprise data into actions inside teams that already buy software aggressively. (hightouch.com) ### Why does the investor mix matter? Because the names tell you this is crossing from venture enthusiasm into institutional conviction. Kleiner Perkins, Sequoia, Thrive, Goldman Sachs Alternatives, Bain Capital Ventures, SoftBank Vision Fund 2, and NVentures are not all making the same style of bet, but they are converging on the same shape of company (hightouch.com)shows up twice here, leading Aidoc and co-leading Hightouch. That is not random. (rogo.ai) ### So what changed this week? The new signal is concentration. Plenty of AI companies are still pitching horizontal promise. But this cluster of financings says late-stage money is rewarding vertical products that map cleanly to revenue teams, care teams, and finance teams. Basically, the market is asking a simpler question now: who already owns a real workflow? (rogo.ai)The $460 million total matters less as a headline number than as a pattern. Investors are still paying up for AI — but right now, they seem most comfortable when the product sits inside a job someone already has to do. (rogo.ai)